ISSN Print: 2394-7500
ISSN Online: 2394-5869
Impact Factor: 5.2
IJAR 2016; 2(4): 214-217
www.allresearchjournal.com
Received: 18-02-2016
Accepted: 22-03-2016

Ghanshyam Biswas
Department of Medical oncology, IMS and SUM Hospital, Siksha O Anusandhan University, K 8, Kalinga Nagar, Bhubaneswar, Odisha, India

Soumya Surath Panda
Department of Medical oncology, IMS and SUM Hospital, Siksha O Anusandhan University, K 8, Kalinga Nagar, Bhubaneswar, Odisha, India

Poonamrani Mishra
Directorate of Medical Research, IMS and SUM Hospital, Siksha O Anusandhan University, K 8, Kalinga Nagar, Bhubaneswar, Odisha, India

Correspondence
Soumya Surath Panda
Department of Medical oncology, IMS and SUM Hospital, Siksha O Anusandhan University, K 8, Kalinga Nagar, Bhubaneswar, Odisha, India

The co-morbidity of diabetes and cancer patients with metallo-beta-lactamase-producing *Pseudomonas aeruginosa* - our experience at a tertiary care teaching hospital

Ghanshyam Biswas, Soumya Surath Panda and Poonamrani Mishra

Abstract
Metallo-beta-lactamase (MBL) - creating Pseudomonas aeruginosa strains have been accounted for to be an essential reason for nosocomial contaminations. There isn't sufficient data from India with respect to their commonness in diabetic and malignant growth patients. The present investigation was attempted over a time of one year from January to December 2015 to examine the occurrence of MBL P. aeruginosa and the clinical result in diabetes and malignant growth patients admitted to IMS and SUM Hospital Bhubaneswar. Two hundred and thirty separates of *P. aeruginosa* were gotten from various examples of patients. These separates were exposed to powerlessness testing to antipseudomonal sedates according to CLSI rules. They were additionally screened for the creation of MBL by circle potentiation testing utilizing EDTA-impregnated imipenem and meropenem plates. Of the 230 detaches of P. aeruginosa, 60 (26%) confines were discovered impervious to carbapenems (both imipenem and meropenem) and 33 (14.3%) were observed to be MBL makers. Of the 33 MBL-creating confines, 24 (72.7%) were diabetic patients, six (18.1%) were malignant growth patients and three (9%) patients had both diabetes and disease. Five (15.1%) patients reacted to the blend treatment of colistin, piperacillin with tazobactam and amikacin, while 28 (84.8%) patients reacted to the mix treatment of amikacin, piperacillin with tazobactam and gatifloxacin. In this way, the quick scattering of MBL makers is troubling and requires the usage of observation ponders as well as legitimate and reasonable choice of anti-infection agents, particularly carbapenems.

Keywords: Carbapenem resistance, metallo-beta-lactamase, *Pseudomonas aeruginosa*

Introduction
Contamination is as yet a successive and difficult issue in malignancy patients treated with chemotherapy who at that point progress toward becoming neutropenic. Regardless of real advances in the treatment of febrile neutropenia (FN), including progressively successful and less dangerous exact expansive range anti-microbials that can be utilized as outpatient treatment in chose generally safe patients, accessibility of better observational antifungal regimens in patients who don't react to standard anti-microbials and expanded utilization of standard and long-acting granulocyte settlement animating components, FN still remains an extremely troublesome helpful issue with a critical death rate. The most extreme bacterial diseases in these patients are circulatory system contaminations (bacteraemia) with or without a site of essential contamination. Elements prescient of bacteraemia in patients with FN have been contemplated in the past [1] yet the model created was not exceptionally accommodating. Bacteraemia amid FN has for the most part been concentrated in patients with hematological malignancies, particularly those accepting haematopoietic undifferentiated cell transplants [2, 3]. In those arrangement, the danger of creating bacteraemia changed with age, kind of harm and sort of transplant. There are less information for strong tumors, however neutropenia is a critical inclining factor [4].
The presentday circumstance for bacteraemia in the FN populace is the subject of this composition. Bacteraemia rates in huge preliminaries testing observational medications for FN stay high, as confirm by an ongoing co-agent aggregate distribution by Viscoli *et al.* [5] in which 29% of FN scenes were related with bacteraemia. In that review, the pathogens causing bacteraemia were roughly similarly partitioned among Grampositive and Gram-

negative life forms. Mortality in patients with bacteraemia is high, particularly when a clinical site of contamination is distinguished [6], which is assigned as 'mind boggling bacteraemia'. In spite of the fact that bacteraemia rates might be a little lower, they are as yet visit. The Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG) preliminaries had a 32% rate of bacteraemia in 1973, which dropped to 22% in 1994 [7]. However, their experience was that the extent of Gram-positive and Gram-negative pathogens causing bacteraemia changed over this timespan. The extent of Gram-negative and Gram-positive pathogens went from 71% and 29%, individually, in 1973– 1978 to 33% and 67%, separately, in 1992– 1994 [7]. This perception has been affirmed by others [8]. The purpose behind the expansion in Gram-positive pathogens is presumably multifactorial. The principle hypothetical reason is the expanded utilization of prophylactic anti-microbials, for example, the fluoroquinolones [9], which will in general lower the quantity of Gram-negative pathogens, in this way the extent of Gram-positive pathogensmay then increment.

Other conceivable causes incorporate the expanded utilization of focal venous catheters in these patients, the picked chemotherapy which may cause huge mucositis, and the expanded utilization of stomach settling agents, which may all choose for Gram-positive microorganisms. This change has chiefly been seen in created nations that can more readily manage the cost of prophylactic anti-infection agents and the utilization of focal catheters, which will be examined further. The principle Gram-negative creatures secluded that reason bacteraemia remain Escherichia coli, Klebsiella sp. what's more, Pseudomonas aeruginosa, as has been the example for a long time. Other Gram-negative creatures are likewise observed however far less regularly.

Coagulase-negative staphylococci (CoNS) remain the fundamental Grampositive pathogens causing bacteraemia, however again an assortment of other Gram-positive creatures are likewise detached less habitually. In this present study, we have evaluated the co-morbidity of cancer with MBL strains for a period of one year.

Materials and Methods

Over the one-year time frame from January to December 2015, 230 disconnects of *P. aeruginosa* were acquired. With Universal wellbeing insurances, tests were gathered from patients admitted to healing facility. They were transported and prepared in the research center immediately. The examples prepared were: tissue (78), respiratory discharges (73), pee (34), swabs discharge/wound (32), blood culture (5), bile (4) and body liquids (4). Tests were prepared and recognized by standard research facility technique [7]. Blood societies were handled utilizing robotized strategy with Versa Trek (Trivitron). Antimicrobial affectability testing was performed on Mueller Hinton Agar plates with financially accessible circles (Hi-Media, Mumbai) by Kirby Bauer plate dissemination technique. The outcomes were recorded and translated according to CLSI recommendations [10]. Pseudomonas aeruginosa segregated from various clinical examples were distinguished by oxidase test and biochemical responses. Pseudomonas aeruginosa ATCC 27853 was utilized as a negative control.

The standard anti-toxin affectability tests were set up for aminoglycosides [amikacin (30 µg), gentamicin (10 µg), netilmicin (30 µg) and tobramycin (10 µg)], cephalosporins [cefoperazone (75 µg), cefepime (30 µg), ceftazidime (30 µg), ceftriaxone (30 µg) and ceftizoxime (30 µg)], fluoroquinolones [ciprofloxacin (5 µg), gatifloxacin (5 µg) and lomefloxacin (10 µg)], carbapenems [imipenem (10 µg) and meropenem (10 µg)], chloramphenicol (30 µg), piperacillin/tazobactam (100/10 µg), aztreonam (30 µg) and colistin (10 µg). Confines were viewed as carbapenem safe when the zone measure around imipenem and meropenem was ≤13 mm, middle of the road 14-15 mm and delicate ≥16 mm. MBL-creating P. aeruginosa was suspected when the disconnect was impervious to meropenem and imipenem. Screening and affirmation for the identification of MBL was finished by circle potentiation test with EDTA-impregnated imipenem plates and EDTA-impregnated meropenem discs [11].

Results

Of the 230 confines of *P. aeruginosa*, 60 (26%) were discovered impervious to carbapenems (both imipenem and meropenem) and 33 (14.3%) were observed to be MBL makers affirmed by the plate potentiation technique. The ATCC 27853 P. aeruginosa did not show any zone measure upgrade with EDTA-impregnated imipenem circles. Of the 33 MBL-delivering confines, 24 (72.7%) were diabetic patients, 6 (18.1%) were malignant growth patients and 3 (9%) patients had both diabetes and disease. Among the disease patients - carcinoma of throat (3), haematolymphoid malignancies with febrile neutropenia (2), carcinoma of lung (2), carcinoma of rectum (1) and carcinoma of prostrate (1). Other co-dreary conditions - Parkinson's disorder (1), Alzheimer's sickness (1), hypothyroidism (3), leptospirosis (1), tuberculosis (4), unending obstructive aspiratory ailment (1) and one patient every who were HIV and hepatitis B positive. Of the 33 patients, 25 (75.7%) were guys and eight (24.2%) were females; middle age of these patients was 68.5 years (50-87 years).

Generally speaking, the anti-microbial affectability example of carbapenem-safe strains is reflected in Fig 1. The anti-toxin affectability example of MBL-positive and - negative strains have been point by point in Table 1. Pursued by aztreonam, gatifloxacin, amikacin, piperacillin/tazobactam and piperacillin. Among malignancy patients, piperacillin demonstrated most extreme affectability pursued by aztreonam, piperacillin/tazobactam and colistin. Among patients with both diabetes and malignant growth, amikacin indicated most extreme affectability pursued by aztreonam [Table 3]. Among the 33 patients with MBL-positive secludes, seven patients terminated; death rate being 21.2%. The prevalent reasons for death were unending renal disappointment because of septicemia, terminal respiratory capture because of septicemia and septicemia with dynamic metastatic carcinoma. Among the 26 patients with MBL-creating P. aeruginosa who endure, 8 (30.7%) required readmissions to the doctor's facility of which seven were diabetic patients conceded with either non-mending wound or urinary tract contaminations and one was a malignant growth quiet conceded on account of weakening in clinical condition because of dynamic ailment. The mean doctor's facility remain of patients in whom MBL makers were detached was 25 days (run 6-44 days).



Fig 1: Overall antibiotic sensitivity pattern of carbapenem-resistant strains

Table 2: Antibiotic sensitivity pattern of MBL-positive and MBL negative strains

Antibiotics µg	MBL-positive n = 33 (% sensitivity)	MBL-negative n = 27 (% sensitivity)
Amikacin	12.1	20
Gentamicin	0	8.3
Netilmicin	0	25
Tobramycin	0	18.1
Cefoperazone	0	15
Cefepime	0	10
Ceftazidime	0	3.8
Ceftriaxone	0	12.1
Ceftizoxime	0	22
Ciproßoxacin	0	18.8
Gatißoxacin	12.1	22.3
Lomeßoxacin	0	14.9
Chloramphenicol	0	20
Piperacillin/tazobactam	9	23.1
Imipenem	0	0
Meropenem	0	0
Aztreonem	21.2	22
Colistin	57.5	66.6
Piperacillin	9	16.6

Discussion

Pseudomonas aeruginosa delivering MBLs was first announced from Japan in 1991. From that point forward, they have been portrayed from different parts of the world including Asia, Europe, Australia, South America and North America [12]. In different examinations over the world, shifting opposition (4-60%) has been seen towards imipenem and meropenem [13, 14]. In 2002 from India, Navneeth *et al*. first detailed MBL creation by P. aeruginosa to be 12% [15]. Since at that point, the rate of MBL creation by P. aeruginosa has been accounted for to be 10-30% from different clinical examples over the country [16]. An investigation directed by Mary *et al*, announced 42% MBL creation by Pseudomonas [17]. Another examination led by Sarkar *et al*, revealed 54.54% MBL generation by Pseudomonas [18]. We report 14.3% MBL creation by P. aeruginosa of the 60 carbapenemresistant detaches. Different techniques have been prescribed for screening MBL. These incorporate the changed Hodge test, twofold plate cooperative energy test utilizing imipenem and EDTA circles or ceftazidime and EDTA circles, EDTA-impregnated imipenem discs [9] and EDTA-impregnated meropenem discs [19]. For MIC recognition of imipenem, the E-test strip is suggested where one-portion of the strip is impregnated with an imipenem slope crosswise over seven weakenings and the other half with another imipenem angle overlaid with a steady centralization of EDTA [19].

Conclusions

Pseudomonas aeruginosa are in charge of 3-7% circulation system contaminations and high death rates (27-48%) in fundamentally sick patients. We report five (15.1%) of 33 circulation system diseases because of P. aeruginosa and seven (21.2%) of 33 mortality cases in ICU patients. The dominating reasons for death were interminable renal disappointment because of septicemia, terminal respiratory capture because of septicemia and septicemia with dynamic metastatic carcinoma. In this way, the quick scattering of

MBL makers is troubling and requires the usage of reconnaissance thinks about as well as legitimate and prudent choice of anti-infection agents, particularly carbapenems.

References

1. Viscoli C, Bruzzi P, Castagnola E *et al*. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1994; 30A: 430-7.
2. Frère P, Baron F, Bonnet C *et al*. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2006; 37:411-18.
3. Nørgaard M, Larsson H, Pedersen G, Schønheyder HC, Sørensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006; 12:217-23.
4. Toussaint E, Bahel-Ball E, Vekemans M *et al*. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer. 2006; 14:763-9.
5. Viscoli C, Cometta A, Kern WV *et al*. Piperacillin–tazobactam monotherapy in high-risk febrile neutropenic cancer patients. Clin Microbiol Infect. 2006; 12:212-16.
6. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25:247-59.
7. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998; 41:13-24.
8. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004; 39(1):S25-31.
9. Cruciani M, Rampazzo R, Malena M *et al*. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: ameta-analysis. Clin Infect Dis. 1996; 23:795-805.
10. Clinical Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. 9th ed. 2006; 2:M2-A9.
11. Hemalatha V, Sekar U, Kamat V. Detection of Metallo betalactamase producing *Pseudomonas aeruginosa* in hospitalized patients. Indian J Med Res. 2005; 122:148-52.
12. Yano H, Kuga A, Okamota R, Kitasato H, Kobayashi T, Inon M. Plasid coded Metallo beta lactamase (imp 6) conferring resistance to carbapenems, especially meropenam. Antimicrob Agents Chemother. 2001; 45:1343-8.
13. Forster DH, Daschner FD. *Acinetobacter* species as nosocomial pathogens. Eur J Clin Microbial Infect Dis. 1998; 17:73-7.
14. Gonlugur U, Bakiri MZ, Akkurt I, Efeoglu T. Antibiotic susceptibility patterns among respiratory isolates of gram negative bacilli in a Turkish University Hospital. BMC Microbiol. 2004; 4:32-6.
15. Navneeth BV, Sridaran D, Sahay D, Belwadi M. A preliminary study on Metallo beta lactamse producing *Pseudomonas aeruginosa* in hospitalized patients. Indian J Med Res. 2002; 116:264-7.
16. Taneja N, Aharwal SM, Sharma M. Imipenem Resistance in non fermenters causing nosocomial urinary tract infection. Indian J Med Sci. 2003; 57:294-9.
17. Jesudason MV, Kandathil AJ, Balaji V. Comparison of two methods to detect carbapenemase and metallo-β-lactamase production in clinical isolates. Indian J Med Res. 2005; 121:780-3.
18. Sarkar B, Biswas D, Prasad R, Sharma JP. A clinical microbiological study on the importance of Pseudomonas in nosocomially infected ICU patients, with special reference to metallo β-lactamase production. Indian J Patho Microbiol. 2006; 49:44-8.
19. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo β-lactamase: The Quiet before the Storm? Clin Microbiol Rev. 2005; 18:306-25.